近日，由博沃生物子公司——武汉博沃牵头承担的“十四五”国家重点研发计划“病原学与防疫技术体系研究”重点专项“呼吸道疾病非注射剂型疫苗研发及靶向递送技术体系研究”项目启动会顺利召开。
Recently, the kick-off meeting of the project of National Key R&D Program of China– "Research and Development of Non-injectable Vaccines for Respiratory Diseases and Targeted Delivery System", led by BravoVax, was successfully held online.
国家卫生健康委医药卫生科技发展研究中心领导、项目负责人博沃生物吴克博士、博沃生物及7家联合申报单位的课题骨干成员以及知名专家复旦大学病原微生物研究所所长姜世勃教授、武汉大学基础医学院侯炜教授、武汉大学疫苗研究院副院长徐可教授参加会议。会上，吴克博士介绍了整体项目研究实施方案，参会人员围绕项目实施计划、课题具体任务、预期成果和效益等方面展开沟通。
Officials from National Health Commission of China, project lead Dr. Wu Ke, key members of the project from BravoVax as well as 7 co-applicants and external experts participated in the meeting. During the meeting, Dr. Wu introduced the overall implementation plans of the project, and the participants exchanged their opinions on the deliverables, timeline, expected outcomes and benefits, etc.
围绕项目实施与管理，国家卫生健康委医药卫生科技发展研究中心赵凯利处长提出，项目单位需要保质保量完成考核任务；项目承担单位、课题承担单位和参与单位需要通力协作，加强沟通交流、信息共享、互助互进；加强多学科融合和多领域交流合作、科技协同创新，联合攻关，力争取得突破性和高水平的成果。同时，项目实施过程中需要注意契约精神，加强责任意识，注意生物安全、国家信息安全，深入相关政策、资金管理的学习。
姜世勃教授、侯炜教授、徐可教授对项目的启动表示祝贺，并针对项目和课题实施的具体细节，提出了切实可行的意见和有益的建议。
此次项目启动会的召开标志着该项目正式进入实施阶段，武汉博沃将做好牵头工作，加强与各联合申报单位的协作，确保整体项目有序推进。
值得一提的是，中国证监会48号公告指出，支持和鼓励国家重大科技专项项目的牵头单位申报科创板上市（来源：http://www.csrc.gov.cn/csrc/c101954/c6940776/content.shtml），博沃生物将把握政策契机，进一步开展公司的资本运作，推动公司获批产品的临床进程，早日实现产品上市，并为后续产品研发和公司发展提供源源不断的动力，最终实现“为生命喝彩”、造福人类的使命！
The convening of the kick-off meeting marks the initiation of this project. As the lead unit, BravoVax will consolidate the collaboration with our partners and ensure the orderly progress of the project.
It is worth mentioning the CSRC (China Securities Regulatory Commission) Announcement [2022] No. 48 noted that “support and encourage lead units of major national science and technology projects to apply for listing on the STAR (Science and Technology Innovation Board) Market”. Under this policy, BravoVax will speed up the listing progress to bring resources to accelerate the clinical trials for earlier market launch and to better leverage our technical strengths on the R&D of more novel vaccines, aiming to realize our mission of "Cheers to life" and benefiting the whole mankind.
关于博沃生物
上海博沃生物科技有限公司 2011年3月成立于上海张江高科技园区，2021年10月迁至北上海生物医药园。2012年12月设立了武汉博沃，是国家级高新技术企业、中国疫苗行业协会理事单位。2020年公司被德勤评为“中国明日之星”，是内地唯一获奖的生物医药企业。公司具有基因编辑/构建/克隆/检测、细菌大规模培养、细胞/病毒大规模培养、生物活性物质制备（多糖、蛋白质、病毒等）、多糖与蛋白质化学结合、新型佐剂、新型制剂、新型检测等多个先进技术平台，满足各类创新型生物医药特别是疫苗开发的需要。博沃生物以满足中国和世界人民健康生活的美好愿景为己任，致力于通过重磅级创新疫苗的开发和市场化运营，成为全球疾病控制领域的主力军。
Shanghai BravoBio Co., Ltd (BravoBio) was established in Zhangjiang Hi-Tech Park in Shanghai in March 2011 and moved to MediPark in North Shanghai in October 2021. Its subsidiary company, Wuhan BravoVax Co., Ltd (BravoVax), was founded in December 2012. BravoVax is a "state level high-tech enterprise" and a council member of China Association of Vaccines (CAV). It was awarded as "China Rising Star" by Deloitte in 2020, becoming the only biopharmaceutical enterprise in Chinese mainland to win this award. The company boasts a number of advanced technology platforms, including gene editing / construction / cloning / detection, large-scale bacterial / cell / virus culture, preparation of bioactive substances (polysaccharide, protein, virus, etc.), chemical combination of polysaccharide and protein, novel adjuvant, new preparation and analytical assays, etc. to meet the needs of developing innovative biologics, especially vaccines. BravoBio has held the mission to improve the quality of people's lives, aiming for a healthier and happier future. The company is active to be a global supplier of high-quality vaccine through development and commercialization of its innovative and blockbuster vaccines, contributing to the control of global diseases.
关注博沃生物
长按二维码 关注我们
公司官网｜www.bravobio.com